title: [Current and future therapy of acromegaly].
abstract: Acromegaly is a rare disease caused by overproduction of growth hormone, which significantly worsens quality of life and increases morbidity and mortality of patients. Modern specialized surgery, radiosurgery, radiotherapy and pharmacotherapy substantially improved therapeutical possibilities and the perspective of patients. Current thera-peutic modalities enable to create individually tailored therapy for the specific patient and suppress the acromegalic activity. Novel forms of currently used active substances and even conceptually new forms of pharmacotherapy are under preparation and testing (eg. octreotide in capsules, CAM2029, Somatoprim, ATL1103).Key words: acromegaly - cabergoline - new drugs - pegvisomant - somatostatin analogs - therapy.
authors.forename: Václav
authors.initials: V
authors.lastname: Hána
mesh_terms: D000172:Acromegaly / Q000628:therapy*; D000236:Adenoma / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000628:therapy*; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D019635:Neurosurgical Procedures; D015282:Octreotide / Q000627:therapeutic use; D011788:Quality of Life; D016634:Radiosurgery; D011878:Radiotherapy; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D004873:Ergolines; C420459:PTR 3173; D019382:Human Growth Hormone; D013004:Somatostatin; D000077465:Cabergoline; C406545:pegvisomant; D015282:Octreotide